EW Stock Recent News

Besides Wall Street's top -and-bottom-line estimates for Edwards Lifesciences (EW), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.

Investors interested in stocks from the Medical - Instruments sector have probably already heard of Integer (ITGR) and Edwards Lifesciences (EW). But which of these two stocks is more attractive to value investors?

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2024 after the market closes on Tuesday February 11, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at ir.edwards.com. About Edwar.

Edwards Lifesciences Corporation EW shares are trading higher on Thursday.

Favorable hospitalization trend, strong adoption of transcatheter heart valves and improved procedural volume are expected to have aided EW in the fourth quarter.

Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

EW stock is on investors' radar courtesy to the promising structural heart opportunities post the divestment of the Critical Care arm.

Texas Pacific Land and Taiwan Semiconductor Manufacturing were top contributors for both the quarter and the year, showcasing strong earnings growth and strategic market positioning. Despite Texas Pacific Land's strong performance, we sold our positions due to overvaluation driven by index additions, with plans to re-invest post-market correction. Edwards Lifesciences' EARLY TAVR trial results highlight significant potential for expanding aortic stenosis treatment, positioning the company for double-digit earnings growth in the coming years.

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, 2025. Bernard Zovighian, chief executive officer, is scheduled to present at 11:15 a.m. PT. Scott Ullem, chief financial officer, will also participate in the conference. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived v.

NEW YORK , Oct. 17, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Edwards Lifesciences Corporation (NYSE: EW) between February 6, 2024 and July 24, 2024, both dates inclusive (the "Class Period"). A class action has already been filed.